Key result
Treatment with an apelin receptor agonist after vasculopathy was established markedly reduced progression of arterial occlusion and decreased immune cell infiltration in mouse heart allografts.
Why the study?
Immune injury of the heart transplant vasculature limits survival and induces poorly characterized repair, while the role of developmental proangiogenic cues in adult vascular repair is largely unknown.
Does apelin receptor agonist treatment reduce transplant vasculopathy and promote vascular repair in heart allografts?
Does apelin receptor agonist treatment reduce transplant vasculopathy and promote vascular repair in heart allografts?
Apelin acts as a key mediator of coronary vascular repair, and treatment with an apelin receptor agonist reduces the progression of immune-mediated transplant vasculopathy in preclinical models.
Apelin-mediated repair may mitigate transplant vasculopathy; leaves open whether targeting it improves long-term graft outcomes.
Sustained, indolent immune injury of the vasculature of a heart transplant limits long-term graft and recipient survival. This injury is mitigated by a poorly characterized, maladaptive repair response. Vascular endothelial cells respond to proangiogenic cues in the embryo by differentiation to specialized phenotypes, associated with expression of apelin. In the adult, the role of developmental proangiogenic cues in repair of the established vasculature is largely unknown. We found that human and minor histocompatibility-mismatched donor mouse heart allografts with alloimmune-mediated vasculopathy upregulated expression of apelin in arteries and myocardial microvessels. In vivo, loss of donor heart expression of apelin facilitated graft immune cell infiltration, blunted vascular repair, and worsened occlusive vasculopathy in mice. In vitro, an apelin receptor agonist analog elicited endothelial nitric oxide synthase activation to promote endothelial monolayer wound repair and reduce immune cell adhesion. Thus, apelin acted as an autocrine growth cue to sustain vascular repair and mitigate the effects of immune injury. Treatment with an apelin receptor agonist after vasculopathy was established markedly reduced progression of arterial occlusion in mice. Together, these initial data identify proangiogenic apelin as a key mediator of coronary vascular repair and a pharmacotherapeutic target for immune-mediated injury of the coronary vasculature.
No takes yet. Share an insight, caveat, or question.
Masoud et al. (2019) studied Chronic allograft vasculopathy. Apelin-17 analog vs. Saline was evaluated on Arterial intimal expansion and immune cell infiltration. Treatment with an apelin receptor agonist after vasculopathy was established markedly reduced progression of arterial occlusion and decreased immune cell infiltration in mouse heart allografts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: